Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 801 - 825 of 15484 in total
Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on...
Approved
Investigational
Matched Description: … [A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole...
Approved
Investigational
Matched Description: … This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. ... Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and
Matched Categories: … Imidazole and Triazole Derivatives ... Triazole and tetrazole derivatives ... azithromycin, fluconazole and secnidazole ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was...
Approved
Investigational
Matched Description: … By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune ... European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Approved
Experimental
A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.
Approved
Matched Description: … A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment …
Matched Categories: … Alimentary Tract and Metabolism ... propantheline and psycholeptics …
Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. As an analogue of cytidine, it...
Approved
Investigational
Matched Description: … As an analogue of cytidine, it is able to incorporate into RNA and DNA, disrupting RNA metabolism and ... inhibiting protein and DNA synthesis. ... [A1407] Due to its anti-neoplastic activity and its ability to inhibit methylation in replicating DNA …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides …
Hydroxocobalamin, also known as vitamin B12a and hydroxycobalamin, is an injectable form of vitamin B 12 that has been used therapeutically to treat vitamin B 12 deficiency. It is also used in cyanide poisoning, Leber's optic atrophy, and toxic amblyopia.
Approved
Matched Description: … It is also used in cyanide poisoning, Leber's optic atrophy, and toxic amblyopia. ... Hydroxocobalamin, also known as vitamin B12a and hydroxycobalamin, is an injectable form of vitamin B …
Matched Categories: … Blood and Blood Forming Organs ... Vitamin B12 and Folic Acid …
Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as solifenacin and darifenacin, it lacks significant antimuscarinic activity, which is...
Approved
Matched Description: … receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and ... amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and ... a comparatively favorable adverse effect profile as compared to other available treatment options, and
Matched Categories: … Genito Urinary System and Sex Hormones ... Drugs for Urinary Frequency and Incontinence …
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers...
Approved
Investigational
Matched Description: … used to detect ALK and ROS1 rearrangements. ... and genetic resistance mechanisms crizotinib is prone to. ... Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Vaborbactam is a β-lactamase inhibitor based on a cyclic boronic acid pharmacophore. It has been used in trials investigating the treatment of bacterial infections in subjects with varying degrees of renal insufficiency. In August 2017, a combination antibacterial therapy under the market name Vabomere was approved by the FDA for...
Approved
Investigational
Matched Description: … Vabomere consists of vaborbactam and [Meropenem] for intravenous administration. ... [Label] The treatment aims to resolve infection-related symptoms of cUTI and achieve negative urine culture …
Matched Categories: … meropenem and vaborbactam …
Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the EGFR gene, which are typically associated with a poorer prognosis (as compared to "classical" EGFR mutants...
Approved
Investigational
Matched Iupac: … -(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate ... propan-2-yl 2-[(4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)phenyl)amino]-4 …
Matched Description: … typically associated with a poorer prognosis (as compared to "classical" _EGFR_ mutants causing NSCLC) and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets.
Approved
Investigational
Matched Description: … are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and
Matched Categories: … Decongestants and Antiallergics …
Strontium chloride (SrCl2) is a salt of strontium and chloride. SrCl2 is useful in reducing tooth sensitivity by forming a barrier over microscopic tubules in the dentin containing nerve endings that have become exposed by gum recession [A33167, A33168]. This kind of barrier protection for tooth hypersensitivity has, however, been...
Approved
Matched Description: … Strontium chloride (SrCl2) is a salt of strontium and chloride. ... protection for tooth hypersensitivity has, however, been superseded by other toothpaste formulations and
A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is...
Approved
Matched Description: … of myasthenia and as a fluorescent probe in HPLC. ... (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment …
Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.
Approved
Withdrawn
Matched Description: … Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity. …
Matched Categories: … Cough and Cold Preparations …
Approved
Experimental
Matched Categories: … Amino Acids, Peptides, and Proteins …
Digoxin Immune Fab is a sheep antibody (26-10) FAB fragment from sheep immunized with the digoxin derivative Digoxindicarboxymethylamine. It is used as an antidote for overdose of digoxin.
Approved
Matched Categories: … Amino Acids, Peptides, and Proteins …
Polistes fuscatus venom protein is an extract of Polistes fuscatus venom. Polistes fuscatus venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as...
Approved
Matched Description: … It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. ... rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and ... It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011 …
Matched Categories: … indacaterol and mometasone ... indacaterol and glycopyrronium bromide ... indacaterol, glycopyrronium bromide and mometasone …
Calcitonin was first discovered in isolated parathyroid tissue as a substance with a serum-calcium-lowering effect. It is constituted as a 32-amino acid single chain polypeptide structure that gets secreted as a regulatory agent in calcium-phosphorus metabolism. It is used as an alternative for people developing antibodies against salmon calcitonin.
Approved
Investigational
Matched Categories: … Sex Hormones and Insulins …
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation....
Approved
Investigational
Matched Iupac: … N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl …
Matched Description: … In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. ... agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and ... These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Cresol is a hydroxytoluene that can be extracted naturally from coal tar or made synthetically. Pure cresol is a mixture of ortho-, meta-, and para- isomers. Cresols are precursors or synthetic intermediates to various other compounds and materials, including plastics, pesticides, pharmaceuticals, disinfectants, and dyes. Ingestion of cresol induces toxicity...
Approved
Matched Description: … pain, and/or vomiting. ... Ingestion of cresol induces toxicity in humans and can lead to burning of the mouth and throat, abdominal ... Pure cresol is a mixture of ortho-, meta-, and para- isomers. …
Raloxifene is a second generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation.[A4979,T28] Exhibiting tissue-specific effects distinct from estradiol, raloxifene is the first of the benzothiophene group of antiestrogens to be labelled a SERM....
Approved
Investigational
Matched Description: … uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation. ... and it does not cause endometrial proliferation. ... generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and
Matched Categories: … Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the...
Approved
Illicit
Investigational
Withdrawn
Matched Description: … increases the risk of heart attack and stroke in patients with a history of heart disease. ... Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide ... In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug …
Matched Categories: … Alimentary Tract and Metabolism ... Serotonin and Noradrenaline Reuptake Inhibitors ... Norepinephrine, Serotonin, and Dopamine Reuptake Inhibitor Anorectic …
Oteracil is an adjunct to antineoplastic therapy, used to reduce the toxic side effects associated with chemotherapy. Approved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with DB09257 and DB09256 within the commercially available product "Teysuno". The main active ingredient in Teysuno is DB09256,...
Approved
Matched Description: … European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with [DB09257] and ... By mimicking a class of compounds called "pyrimidines" that are essential components of RNA and DNA, ... 5-FU is able to insert itself into strands of DNA and RNA, thereby halting the replication process necessary …
Displaying drugs 801 - 825 of 15484 in total